FENAMIN-250 CAPSULES

Patient Information leaflet

                                INDICATIONS [/za_1038.html#1]
  [/za_1038.html#1]     [/za_1038.html#1]
CONTRA-INDICATIONS [/za_1038.html#1]
      [/za_1038.html#1]
DOSAGE [/za_1038.html#1]
      [/za_1038.html#1]
SIDE-EFFECTS [/za_1038.html#1]
  [/za_1038.html#1]     [/za_1038.html#1]
PREGNANCY [/za_1038.html#1]
      [/za_1038.html#1]
OVERDOSE [/za_1038.html#1]
    
IDENTIFICATION [/za_1038.html#1]
  [/za_1038.html#1]    PATIENT INFORMATION
FENAMIN-250 CAPSULES
FENAMIN-500 TABLETS
FENAMIN SUSPENSION
SCHEDULING STATUS:
S3
S2 (see indications below)
PROPRIETARY NAME
(and dosage form):
FENAMIN-250 CAPSULES
FENAMIN-500 TABLETS
FENAMIN SUSPENSION
COMPOSITION
Capsules containing 250 mg mefenamic acid
Film coated tablets containing 500 mg mefenamic acid
Suspension containing in each 5 mL 50 mg 
MEFENAMIC ACID
PRESERVATIVES:
 
Methylparaben 0,03% m/v
 
Propylparaben 0,015% m/v
 
Butylparaben 0,015% m/v
PHARMACOLOGICAL CLASSIFICATION:
A 2.7 Antipyretic and anti-inflammatory analgesics
PHARMACOLOGICAL ACTION:
Fenamin has anti-inflammatory activity and also antipyretic and analgesic properties. In analgesia it has a central as
well as a peripheral action. Fenamin appears to owe those properties to its capacity to inhibit cyclo-oxygenase. Also it
appears to antagonise certain effects of prostaglandins.
INDICATIONS:
S3: The relief of mild to moderate pain arising from rheumatic conditions, soft-tissue injuries, other painful
musculoskeletal conditions and dysmenorrhoea.
S2: Treatment of post traumatic conditions such as pain, swelling and inflammation for a maximum period of 5 days.
CONTRA-INDICATIONS:
Sensitivity to mefenamic acid and other non-steroidal anti-inflammatory agents, with prostaglandin synthetase inhibiting
activity. The possibility of cross-sensitivity among non-steroidal anti-inflammatory agents exists.
Fenamin is contra-indicated in patients with ulcerat
                                
                                Read the complete document